Phoenix Bio

NEWS

PhoenixBio Announces Strategic Acquisition of KMT Hepatech, Inc.

PhoenixBio Announces Strategic Acquisition of KMT Hepatech, Inc.

PhoenixBio Co., Ltd. today announced that it has entered into a definitive agreement to acquire KMT Hepatech, Inc., a privately held contract research organization focused on providing services with a chimeric mouse model. KMT will wholly become a part of the PhoenixBio group effective November 30th, 2017.